Cresset Asset Management’s Emergent Biosolutions EBS Stock Holding History

Cresset Asset Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,478	Closed	-$231K	–	1033
2021 Q1	$231K	Buy	+2,478	New	+$254K	﹤0.01%	796
2019 Q2	–	Sell	-118	Closed	-$6K	–	803
2019 Q1	$6K	Hold	118	–	–	﹤0.01%	1296
2018 Q4	$7K	Buy	+118	New	+$7.61K	﹤0.01%	924

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cresset Asset Management's EBS Position: Q2 2021 in Review

Cresset Asset Management sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 2,478 shares — an estimated $231K sold.

Cresset Asset Management first reported a position in EBS in Q4 2018 and held it in 3 quarters. The position peaked at $231K in Q1 2021. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

Cresset Asset Management reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
Cresset Asset Management sold 2,478 Emergent Biosolutions shares in Q2 2021, an estimated $231K.
Cresset Asset Management first reported a position in Emergent Biosolutions in Q4 2018 and held it in 3 quarters.
Cresset Asset Management's Emergent Biosolutions position peaked at $231K in Q1 2021.
290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Cresset Asset Management's 13F filing for Q2 2021, filed 10 Aug 2021.